Skip to main content

Yoon Kyung Jeon

Seoul National University · 医学

研究室紹介

Professor Yoon Kyung Jeon's research lab focuses on the tumor microenvironment, particularly the interplay between immune checkpoint molecules like PD-L1 and PD-1, tumor-infiltrating immune cells, and cancer metabolism in various malignancies, including non-small cell lung cancer and diffuse large B-cell lymphoma. The lab investigates molecular mechanisms underlying immune evasion, such as the regulation of PD-L1 by oncogenic drivers like EML4-ALK and the role of immune cell subsets like tumor-associated macrophages and Tregs in disease progression and prognosis. Additionally, the lab explores oncogenic signaling pathways, including Pellino-1-mediated ubiquitination, in tumorigenesis and metabolic reprogramming in cancer cells. Their work integrates clinical pathology with molecular oncology to identify novel therapeutic targets and biomarkers.

immune checkpointtumor microenvironmentPD-L1cancer metabolismlymphoma

Research Overview

Papers
432
Total Citations
13,690
Papers (5y)
122
Primary Field
医学

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
122total
2022
2023
2024
2025
2026
Citations per year (5y)
675total
20222023202420252026

Selected Papers

15
1
Article|186 citations·2015
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
Moon‐Young Kim, Jaemoon Koh, Sehui Kim, Heounjeong Go, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1Lung Cancer
OncologyMedicine
2
Article|181 citations·2015
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas
Sehui Kim, Moon‐Young Kim, Jaemoon Koh, Heounjeong Go, Dong Soo Lee, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1European Journal of Cancer
Pulmonary and Respiratory MedicineMedicine
3
Article|165 citations·2016
PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
Sehui Kim, Jaemoon Koh, Moon‐Young Kim, Dohee Kwon, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1Human Pathology
OncologyMedicine
4
Article|159 citations·2015
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh, Heounjeong Go, Bhumsuk Keam, Moon‐Young Kim, Soo Jeong Nam, Tae Min Kim, Se‐Hoon Lee, Hye Sook Min, Young Tae Kim, Dong‐Wan Kim, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1Modern PathologyOA
Pulmonary and Respiratory MedicineMedicine
5
Article|154 citations·2015
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
Jaemoon Koh, Ji-Young Jang, Bhumsuk Keam, Sehui Kim, Moon‐Young Kim, Heounjeong Go, Tae Min Kim, Dong‐Wan Kim, Chul Woo Kim, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1OncoImmunologyOA

Programmed cell death (PD)-1/PD-1 ligand-1 (PD-L1)-targeted therapy has emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK regulates PD-L1 expression in lung cancer remains unknown. A total of 532 pulmonary adenocarcinomas (pADCs), including 58 ALK-translocated tumors, were immunohistochemically evaluated for PD-L1 and PD-1. H23 (EGFRWild-typeEML4-ALK−PD-L1Low) and H2228 (EGFRWild-typeEML4-ALK+PD-L1High) cells were transfected with EML4-ALK or ALK short interf

Pulmonary and Respiratory MedicineMedicine
6
Article|153 citations·2015
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
Dohee Kwon, Sehui Kim, Pil‐Jong Kim, Heounjeong Go, Soo Jeong Nam, Jin Ho Paik, Young A Kim, Tae Min Kim, Dae Seog Heo, Chul Woo Kim, Yoon Kyung Jeon
SJR Q1Histopathology

AIMS: To investigate the clinicopathological characteristics of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expression in the tumour microenvironments of diffuse large B cell lymphoma (DLBCL). METHODS AND RESULTS: Tumour tissues from 126 DLBCL patients were immunostained for PD-L1 and PD-1. The expression of PD-L1 by tumour cells and/or tumour-infiltrating immune cells (mainly macrophages) was evaluated, and the number of tumour-infiltrating PD-1(+) cells was assess

OncologyMedicine
7
Article|150 citations·2014
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
Jae‐Kyung Won, Bhumsuk Keam, Jiwon Koh, Heechun Cho, Yoon Kyung Jeon, T. M. Kim, S.H. Lee, D.S. Lee, D.W. Kim, Doo Hyun Chung
SJR Q1Annals of Oncology
Pulmonary and Respiratory MedicineMedicine
8
Article|124 citations·2021
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape
Seung Geun Song, Sehui Kim, Jaemoon Koh, Jeemin Yim, Bogyeong Han, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1Cancer Immunology ImmunotherapyOA
OncologyMedicine
9
Article|118 citations·2014
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Soo Jeong Nam, Heounjeong Go, Jin Ho Paik, Tae‐Min Kim, Dae Seog Heo, Chul Woo Kim, Yoon Kyung Jeon
SJR Q2Leukemia & lymphoma/Leukemia and lymphoma

Tumor-associated macrophages (TAMs) and regulatory T-cells (Tregs) play an important role in the tumor microenvironment. Here, we investigated the prognostic implications of TAMs and Tregs in 165 diffuse large B-cell lymphomas (DLBCLs) using immunohistochemistry. Survival analysis was performed among 109 DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). An increase in CD68 (+) cells was related to improved overall survival (OS) (p = 0.033). By con

ImmunologyImmunology and Microbiology
10
Article|104 citations·2017
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
Sehui Kim, Jaemoon Koh, Dohee Kwon, Bhumsuk Keam, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung
SJR Q1European Journal of Cancer
OncologyMedicine
11
Article|103 citations·2019
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
Sehui Kim, Ji-Young Jang, Jaemoon Koh, Dohee Kwon, Young A Kim, Jin Chul Paeng, Chan‐Young Ock, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dae Seog Heo, Doo Hyun Chung
SJR Q1Journal of Experimental & Clinical Cancer ResearchOA

Abstract Background We investigated the role of PD-L1 in the metabolic reprogramming of non-small cell lung cancer (NSCLC). Methods Changes in glycolysis-related molecules and glycolytic activity were evaluated in PD-L1 low and PD-L1 high NSCLC cells after transfection or knockdown of PD-L1 , respectively. Jurkat T-cell activation was assessed after co-culture with NSCLC cells. The association between PD-L1 and immune response-related molecules or glycolysis were analyzed in patients with NSCLC

Cancer ResearchBiochemistry, Genetics and Molecular Biology
12
Article|87 citations·2006
Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer
Yoon Kyung Jeon, Sook-Whan Sung, Jin-Haeng Chung, Weon Seo Park, Jeong‐Wook Seo, Chul Woo Kim, Doo Hyun Chung
SJR Q1Lung Cancer
Pulmonary and Respiratory MedicineMedicine
13
Article|82 citations·2016
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis
Wook Youn Kim, Ho Young Jung, Soo Jeong Nam, Tae Min Kim, Dae Seog Heo, Chul Woo Kim, Yoon Kyung Jeon
SJR Q1Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
OncologyMedicine
14
Article|76 citations·2016
Pellino-1 promotes lung carcinogenesis via the stabilization of Slug and Snail through K63-mediated polyubiquitination
Yoon Kyung Jeon, Chung Kwon Kim, Kyung Rim Hwang, Hye-Young Park, Jaemoon Koh, Doo Hyun Chung, Chang‐Woo Lee, Geun‐Hyoung Ha
SJR Q1Cell Death and DifferentiationOA

Pellino-1 is an E3 ubiquitin ligase acting as a critical mediator for a variety of immune receptor signaling pathways, including Toll-like receptors, interleukin-1 receptor and T-cell receptors. We recently showed that the Pellino-1-transgenic (Tg) mice developed multiple tumors with different subtypes in hematolymphoid and solid organs. However, the molecular mechanism underlying the oncogenic role of Pellino-1 in solid tumors remains unknown. Pellino-1-Tg mice developed adenocarcinoma in the l

BiotechnologyBiochemistry, Genetics and Molecular Biology
15
Article|69 citations·2015
Epstein-Barr virus–positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features
Yoon Kyung Jeon, Jo-Heon Kim, Ji‐Youn Sung, Jae Ho Han, Young-Hyeh Ko
SJR Q1Human PathologyOA
Pathology and Forensic MedicineMedicine

Research Areas

OncologyPulmonary and Respiratory MedicinePathology and Forensic MedicineMolecular BiologyImmunologyRheumatology

Yoon Kyung Jeonの研究をNubintでさらに深く

この研究室の論文をアプリで開き、AIと共に読み、要約し、引用しましょう。